Erythromycin vs placebo
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
- no estimate extracted1 study · 34 participantsModerate
Findings
What do systematic reviews say?
11 questions · 11 findings · 2 reviews · Skin
No studies found 7 · 63.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 9.1%Moderate 3 · 27.3%High 0 · 0%
Erythromycin vs placebo
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Erythromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (low certainty).
1 finding from 1 review
- RR 4.02 [0.28, 56.61]2 studies · 86 participantsLow
Erythromycin vs placebo
Adverse events: minor gastrointestinal symptoms · pityriasis rosea
Erythromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 2 [0.2, 20.04]1 study · 34 participantsModerate
Erythromycin vs placebo
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Erythromycin vs placebo
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
- no estimate extracted1 study · 34 participantsModerate
Erythromycin vs placebo
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Erythromycin vs no treatment
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
- Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Erythromycin vs no treatment
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
- Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Erythromycin vs no treatment
Proportion of participants with adverse events and severe adverse events · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
- Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Erythromycin vs no treatment
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
- Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Erythromycin vs no treatment
Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
- Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found